Patents by Inventor Zhibao Mi

Zhibao Mi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120219982
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Application
    Filed: May 1, 2012
    Publication date: August 30, 2012
    Applicant: Precision Therapeutics, Inc.
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin
  • Patent number: 8187800
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: May 29, 2012
    Assignee: Precision Therapeutics, Inc.
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin
  • Publication number: 20100216168
    Abstract: The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-?1, TGF-?2, TGF-?3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.
    Type: Application
    Filed: March 24, 2008
    Publication date: August 26, 2010
    Applicant: PRECISION THERAPEUTICS, INC.
    Inventors: Jamie Heinzman, Stacey Brower, Jason Bush, Zhibao Mi
  • Publication number: 20090104647
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 23, 2009
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin
  • Publication number: 20070253968
    Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
    Type: Application
    Filed: October 27, 2006
    Publication date: November 1, 2007
    Inventors: Paul Robbins, Zhibao Mi, Raymond Frizzell, Joseph Glorioso, Andrea Gambotto, Jeffrey Mai
  • Patent number: 7264948
    Abstract: The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, ?F508 CFTR.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: September 4, 2007
    Assignee: University of Pittsburgh
    Inventors: Paul D Robbins, Raymond Frizzell, Zhibao Mi, Fei Sun
  • Patent number: 6881825
    Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of the peptides, and methods of use for the peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: April 19, 2005
    Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
    Inventors: Paul D. Robbins, Zhibao Mi, Raymond Frizzell, Joseph C. Glorioso, Andrea Gambotto
  • Publication number: 20050074884
    Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
    Type: Application
    Filed: August 26, 2004
    Publication date: April 7, 2005
    Inventors: Paul Robbins, Zhibao Mi, Raymond Frizzell, Joseph Glorioso, Andrea Gambotto
  • Publication number: 20040115770
    Abstract: The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp7O and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, &Dgr;F508 CFTR.
    Type: Application
    Filed: August 28, 2003
    Publication date: June 17, 2004
    Inventors: Paul D. Robbins, Raymond Frizzell, Zhibao Mi, Fei Sun
  • Publication number: 20030219826
    Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
    Type: Application
    Filed: February 12, 2003
    Publication date: November 27, 2003
    Inventors: Paul D. Robbins, Zhibao Mi, Raymond Frizzell, Joseph C. Glorioso, Andrea Gambotto, Jeffrey C. Mai
  • Publication number: 20030104622
    Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
    Type: Application
    Filed: February 13, 2002
    Publication date: June 5, 2003
    Inventors: Paul D. Robbins, Zhibao Mi, Raymond Frizzell, Joseph C. Glorioso, Andrea Gambotto
  • Patent number: 6331565
    Abstract: This invention relates to the new use of dicaffeoylquinic acid derivatives for treating Hepatitis B and diseases associated with retrovirus (such as HIV), the new caffeoylquinic acid derivatives and the composition containing the same.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: December 18, 2001
    Assignee: Institute of Radiation Medicine Academy of Military Medical Sciences of the PLA
    Inventors: Junxing Dong, Zhongming Tang, Zhibao Mi, Bingji Wang